DOCTOR'S VIEW ARCHIVE
Diabetics: Is the New Inhaled Insulin Right for You?
The U.S. Food and Drug Administration (FDA) has approved the use of an inhaled insulin preparation for the treatment of adults with both Type 1 and Type 2 diabetes. The first new insulin formulation since its discovery in the 1920s, the drug is marketed under the name Exubera and was approved for adult use on January 27, 2006. Exubera is a powdered, recombinant (genetically engineered), human insulin that has been in development for many years by a team of pharmaceutical companies - Pfizer, Sanofi-Aventis, and Nektar Therapeutics.
The Exubera inhaler is larger than the familiar inhalers used to treat asthma and other breathing conditions. In its most compact form, it is about the size of a flashlight. A retractable tube must be pulled out and a blister package of insulin inserted before the device is used.
To date, the safety and effectiveness of Exubera have been studied in about 2,500 adults with both Type 1 and Type 2 diabetes. However, the FDA notes that some groups of people should not use the new inhaled insulin until further studies of its effectiveness and safety are completed. Specifically, those interested in Exubera should note the following:
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions